EGFR and non-small cell lung carcinoma: Of note, the median PFS of ABCP therapy was better than that of chemotherapy when the PD‐L1 expression was positive and significantly worse when the PD‐L1 expression was negative, even in EGFR‐mutated NSCLC patients.